People

The People

Governance grade: C. Molina has the architectural trappings of good governance — independent chair, all-independent key committees, single voting class, clawback policy, prohibition on pledging and hedging — but the 2025 say-on-pay vote collapsed to 40% support (vs. a five-year average above 90%) after the board paid an outgoing 69-year-old CEO a one-time retention grant on top of an already-rich annual package. The compensation framework has since proven its pay-for-performance bite — every PSU outstanding is on track to forfeit and 2025 cash bonuses paid zero — but insider ownership is thin (combined directors and officers hold just 1.44% of shares), the board is aging, and a Wolf/Soistman director interlock from eHealth raises questions about independence in fact rather than form.

The People Running This Company

Molina is run by a tight, finance-heavy team assembled by CEO Joe Zubretsky after the 2017 founding-family ouster. Five of the six executive officers came from Aetna, Hanover, or Health Net — managed-care lifers, not founders. Zubretsky himself is the central question: a 69-year-old CEO whose contract was extended in late 2024 to keep him through year-end 2027, a decision that triggered investor revolt and now looks economically irrelevant because the linked performance targets are expected to forfeit.

The notable absences also matter. There is no founder presence in management or the boardroom; the Molina family was removed in May 2017 after poor results and has no operational role. Tenure imbalance also flags succession risk: Bacon (Medicaid, the 87% revenue segment) has been in the EVP seat less than three years, and Woys, the COO, is 67. Zubretsky's retention through 2027 is contractual, but the question of who succeeds him is unanswered in the public record.

What They Get Paid

CEO Zubretsky's reported 2025 pay was $18.3M — almost entirely fixed salary ($1.6M) and grant-date PSU/RSA values ($16.2M). But the economic outcome was sharply different: the compensation committee paid $0 in cash bonus to all five NEOs in February 2026, and the PSU tranches granted in 2023, 2024, 2025, plus the special retention grants made in late 2024, are now all expected to forfeit without payment. The "compensation actually paid" line in the pay-versus-performance table came in at negative $15.3M for the CEO — the system did punish bad performance.

The optics problem: Zubretsky's headline pay is roughly 12x the next-highest NEO and the CEO pay ratio against the median employee is 228:1 (107:1 if the expected-to-forfeit 2025 PSUs are excluded). Both numbers are high for a $42B-premium managed-care insurer whose 2025 net income fell 60% and whose share price underperformed peers by ~80 percentage points over five years. The committee's response — that the framework "worked" because PSUs are zero and cash bonus is zero — is technically correct but does not undo the grant-date optics.

CAP collapsed from $76M in 2021 to negative $15M in 2025, mirroring the TSR underperformance — Molina has fallen 18% from base while peers compounded to $162. So while the headline grant-date numbers look high, the realized outcomes track shareholders' downside. The credibility problem is forward-looking, not backward: investors do not believe the special $36-EPS-by-2027 grant was warranted given the CEO's age and the rate-cycle visibility.

Are They Aligned?

This is the weakest section. Combined ownership by the entire 15-person executive and director group is 749,230 shares — 1.44% of the company. The CEO alone holds 373,465 shares (roughly $52M at $140); no other officer holds material wealth in stock relative to their cash and equity compensation runs.

Institutional control is dominant — the top four asset managers hold ~32% — which is normal for a Russell-listed midcap but also means alignment with long-term value creation rests on management's own equity, not founder-family ownership. The 1.44% insider stake is meaningfully below the typical 3–5% seen at well-aligned managed-care peers.

Per Simply Wall St's Form 4 aggregation, insiders sold $4.0M of stock over the last 12 months and bought $1.7M — a net seller posture but at modest absolute scale. The single largest disclosed open-market sale of 2025 was Chairman Schapiro selling 357 shares on 11/24/2025 at $143 (~$51K). Most other Form 4 activity was tax-withholding on RSU vests, which is not a directional signal. Importantly, no insider stepped up to buy as the stock fell from $300+ in early 2024 to the low-$140s by late 2025 — a missed signal of conviction.

Capital allocation is shareholder-friendly on shares but questionable on timing: the company has repurchased roughly $2B of stock since 2022, with $500M remaining of the April 2025 $1B authorization. The diluted share count fell from 58.1M to 52.9M — a real reduction, not just an SBC offset. But much of the 2024 and early-2025 buybacks executed at prices above $250, well above the current $140s. The Board approved a $1B authorization in April 2025 just before the 60% earnings collapse — a classic peak-cycle repurchase mistake.

Related-party transactions are minor: the only disclosed item for 2025 is the employment of Vice-Chair Romney's son, George Romney, at $157,590 base salary. Not material in dollars, but a related-party relationship that has been allowed to persist for years.

Board Quality

Ten directors, nine independent, separate independent chair (Dale Wolf), all-independent audit/compensation/governance/compliance committees. On paper this is a strong board. In practice the matrix exposes three issues: age (Romney is 82, Orlando is 74, Wolf is 71 — five of ten are 70+), tenure (Romney 23 years, Orlando 21 years — both well past common best-practice limits, despite the 12-year cap that was set in 2020 for newly elected directors), and a director interlock with eHealth (Wolf was chair of eHealth's board through June 2024; Soistman was CEO of eHealth 2021–2025 and is now a Molina nominee).

The board is heavily weighted toward managed-care operating veterans (Wolf, Zoretic, Soistman, Zubretsky) and financial expertise (Brasier, Orlando, Schapiro, Grohowski) — sensible for an insurer. But it is light on clinical, technology, and cybersecurity expertise, has only two women (Romney 82 and Brasier 67), and the new nominee Soistman creates a meaningful overlap with Chair Wolf via their shared service at eHealth. Notably, the 2025 say-on-pay vote — engineered by the very compensation committee chaired by Wolf — failed; the same Wolf is leading the "engagement" response. There is no evidence the committee has structurally changed how it sets pay, only that it has expanded the disclosure section.

The Verdict

Grade: C. Molina is not governed badly in any structural or legal sense — independent chair, all-independent committees, single voting class, working clawback, no pledging or hedging, a real say-on-pay mechanism that visibly bit when the board acted aggressively. The pay framework's economic outcome in 2025 — zero cash bonus, ~$0 from PSUs, negative $15M "actually paid" — is exactly what shareholders should want when results miss.

Strongest positives:

1. Pay-for-performance machinery worked: every variable comp pool zeroed when 2025 collapsed.
2. Aggressive share repurchases reduced diluted share count from 58.1M to 52.9M.
3. The 2017 ouster of the founding family demonstrates the board can act when management underperforms.

Real concerns:

1. 2025 say-on-pay drew only 40% support after the one-time CEO retention grant — investors do not buy the board's compensation judgment.
2. Combined insider ownership is just 1.44%; no insider stepped up to buy as the stock fell from $300+ to the $140s.
3. Five of ten directors are 70+, with two having 21+ years of tenure, and the Wolf/Soistman eHealth overlap raises recruitment-network concerns.
4. Buybacks were executed largely above $250 just before earnings collapsed 60%.

The one thing that would change the grade:

• Upgrade to B if the 2026 say-on-pay vote recovers above 70% AND the company communicates a credible succession plan for Zubretsky before his contract end in late 2027.
• Downgrade to D if a second consecutive failed say-on-pay vote occurs, or if a new related-party transaction or director controversy surfaces alongside continued operating disappointment.